Bioceltix S.A.

Warsaw Stock Exchange BCX.WA

Bioceltix S.A. Current Liabilities for the year ending December 31, 2023: USD 542.53 K

Bioceltix S.A. Current Liabilities is USD 542.53 K for the year ending December 31, 2023, a 5.75% change year over year. Current liabilities are obligations that are expected to be settled within one year, including accounts payable, short-term debt, and other current liabilities.
  • Bioceltix S.A. Current Liabilities for the year ending December 31, 2022 was USD 513.04 K, a 8.79% change year over year.
  • Bioceltix S.A. Current Liabilities for the year ending December 31, 2021 was USD 471.58 K, a 32.66% change year over year.
  • Bioceltix S.A. Current Liabilities for the year ending December 31, 2020 was USD 355.47 K.
Key data
Date Current Liabilities Total Non-Current Liabilities Shareholders' Equity Long-Term Debt
Market news
SV Wall Street
Warsaw Stock Exchange: BCX.WA

Bioceltix S.A.

CEO Mr. Lukasz Bzdzion
IPO Date Nov. 8, 2021
Location Poland
Headquarters Building III
Employees 28
Sector Healthcare
Industries
Biotechnology Pet Food Pharmaceuticals
Description

Bioceltix S.A. engages in the development of stem cell-based biopharmaceuticals for veterinary use. Its products include BCX-CM-J, a stem-cell based biological drug for the treatment of degenerative joint lesions in dogs; BCX-CM-AD, a biological drug candidate based on allogeneic stem cells for the treatment of atopic dermatitis in dogs; and BCX-EM, a biological drug candidate based on allogeneic mesenchymal stem cells for the treatment of arthritis in horses. The company was incorporated in 2018 and is based in Wroclaw, Poland.

StockViz Staff

February 8, 2025

Any question? Send us an email